My Profile

Search abstracts

Lewis Sheiner


2017
Budapest, Hungary



2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
KÝbenhavn, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland



Printable version

PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
ISSN 1871-6032

Reference:
PAGE 22 (2013) Abstr 2865 [www.page-meeting.org/?abstract=2865]


PDF poster/presentation:
Click to open Click to open

Poster: Estimation Methods


I-09 Tarjinder Sahota Real data comparisons of NONMEM 7.2 estimation methods with parallel processing on target-mediated drug disposition models

Tarjinder Sahota (1), Enrica Mezzalana (1), Alienor Berges (1), Duncan Richards (2), Alex Macdonald (1), Daren Austin (1), Stefano Zamuner (1)

(1) Clinical Pharmacology Modelling and Simulation, GSK, UK. (2) Academic DPU, GSK, UK

Objectives: Target-mediated drug disposition (TMDD) models are increasingly used to describe drug-target interactions. In practice, however, their use can come with long running times and convergence problems in NONMEM. Gibiansky et al., have previously used simulated data to investigate the accuracy and parallel processing efficiency of TMDD models with NONMEM 7.2.0 estimation methods1. They found all methods except BAYES gave accurate parameter estimates, standard error estimates, and high (85-95%) parallel processing efficiency. Importance sampling (IMP) was found to be the fastest exact likelihood method in terms of run time.
Here we detail our modelling experience of clinical studies using FOCE and IMP with parallelisation on two separate compounds exhibiting TMDD. We evaluate the methods for model stability and parallel processing efficiency.

Methods: Compound 1: CPHPC, a small molecule targeting serum amyloid P component (SAP), a soluble target. CPHPC was administered to patients and plasma CPHPC and SAP sampling were collected from baseline (day ‑1) to follow up (day 28). Only total concentrations (free + bound fractions of CPHPC-SAP) in plasma were available.  Limited SAP recovery information was available.
Compound 2: Otelixizumab, a monoclonal antibody which is directed against human CD3ε on T lymphocytes4. Free drug in serum and free, bound and total receptors on T cells were measured using immunoassay and flow cytometry, respectively. However ~70% of free drug concentrations were below the limitation of quantification (BLQ).
Estimation method evaluation was via comparison of OFV with exact likelihood OFV (ISAMPLE=20000), run time, minimisation success criteria and parallel efficiency.  Parallelisation was performed using MPI on up to four cores.

Results: FOCE linearisation was found to heavily bias the OFV in some instances. Model convergence can also fail with FOCE when datasets are associated with limitations in sampling schedule and bioanalytical assay (e.g. measurements limited to total concentrations or significant proportions of BLQ data). In contrast, both models performed well with IMP. Diagnostic performance was good and key parameters were in line with previously published values. Moreover, IMP gave significant run time improvements over FOCE. Use of parallel processing with MPI efficiently reduced run time further to levels where model development and exploration were feasible.

Conclusions: IMP is recommended over FOCE for TMDD models.

References:
[1] Gibiansky, L., et al. (2012) J. PKPD. 39 (1) 17-35
[2] A. Berges PAGE 2012
[3] T. Sahota PAGE 2012
[4] E. Mezzalana PAGE 2012